GlassScriptPhysician profile
Sara T Strasser
NPI 1407824139
$3,836.23
in general payments reported to CMS, 2019-2025
15 companies · $576 in 2025
The $576 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $170 · 2021: $424 · 2022: $734 · 2023: $721 · 2024: $622 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,002.26 | 2022-2025 | Infuse |
| Abbvie INC. | $611.25 | 2022-2025 | |
| Coopervision INC. | $532.66 | 2019-2025 | Myday Contact Lens, Cvi Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $399.62 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $301.83 | 2019-2021 | |
| Allergan, INC. | $208.12 | 2019-2022 | |
| Harrow Eye, LLC | $196.17 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $141.10 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $122.43 | 2022-2024 | Tearcare System |
| Regeneron Healthcare Solutions, INC. | $120.02 | 2019 | |
| Sun Pharmaceutical Industries INC. | $96.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.68 | 2022-2023 | |
| Oyster Point Pharma, INC. | $22.54 | 2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $21.32 | 2025 | |
| Dompe US, INC. | $18.67 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Strasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.